Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Prostate cancer
      • Bladder cancer
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • Media
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
    • Our annual accounts
    • Pelican Cancer Foundation – What next?
    • Support Us
    • Job opportunities
    • Partners
  • Workshops
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Videos
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Prostate Cancer Research
      • Focal therapy and HIFU research
      • MRI research for prostate cancer
      • Prostate cancer colloquiums
      • FORECAST
      • Trachtomap
      • Papers of interest
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Bladder cancer research
      • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Jay’s story (bladder cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Prostate cancer
      • Our prostate cancer team
      • Prostate cancer treatment options
      • Pelican’s position
    • Bladder cancer
      • Blue light cystoscopy
      • Bladder cancer – useful contacts
    • Pseudomyxoma peritonei
    • Kidney cancer
      • Our kidney cancer team
      • Kidney cancer – useful contacts
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
      • How your donations are spent
    • Fundraising
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
      • Our events
    • Leaving a Legacy
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Charity of the Year partnerships
    • Pelican Film Society
  • Shop
  • Events
  • Contact us

Prostate cancer treatment options

(after prostate cancer has been diagnosed)

*Please note that these are general options applying to Basingstoke practice. If you have questions or concerns about your specific diagnosis and treatment, you should talk to your specialist nurse.

Prostate cancer treatment depends on the stage of the cancer. We need to know if it is localised to the gland only, or if it has spread beyond the capsule which envelopes the gland. We then need to assess to what level it has spread – locally, to lymph glands, or to bone and other organs.

Prostate cancer which is localised to the gland has a number of treatment options:

Active surveillance

As many men with early prostate cancer die with the disease rather than from it, we can manage early prostate cancer by regular monitoring with clinical examination of the prostate and a regular blood test. If there are any signs from this that the disease may be progressing then other treatments can be offered.

Radical treatment (radiotherapy or surgery)

This involves treating the whole gland to destroy it and some surrounding structures.

Hormonal therapy

Prostate cancer tissue is dependent on testosterone to survive, so using hormonal therapy to reduce or make zero the level of testosterone in your blood can control the prostate cancer. However, after a number of years, some prostate cancer cells adapt so that they are no longer dependent on testosterone and hormonal therapy no longer helps.

Energy based modalities that can deliver therapy for prostate cancer

Crytherapy – probes inserted into the prostate via the perineum and undergo freezing to temperatures of  -40°C. Two freeze-thaw cycles are required to destroy cells using coagulative necrosis

High-intensity focused ultrasound (HIFU) – uses both thermal (temperatures ˃56°C) and mechanical energy to destroy tissue. It is usually delivered using a transrectal probe under ultrasound guidance, there is hope that new devices using MRI-guidance and ultra-urethral HIFU will be developed

Photodynamic therapy – a photosensitizer (via injected intravenous) by a specific wavelength of light transmitted through laser fibres inserted transperineally into the prostate to create cell damage and tissue necrosis through the production of reactive oxygen species. This technique is being evaluated within regulatory trials

Laser-based photothermal therapy – Laser fibres, inserted transperineally or transrectally, cause coagulative necrosis through a direct thermal effect, with monitoring of effect using MRI-thermometry

Brachytherapy – Low dose-rate brachytherapy involves implantation of small radioactive seeds. High dose-rate brachytherapy involves inserting a source of high does-rate radiation into the prostate gland for a few minutes

Irreversible electroporation therapy – an electric field to open nano-sized pores in the cell membrane, which when applied with sufficient amplitude and duration causes permanent damage to the cell membrane

Radiofrequency therapy– High-frequency alternating current (in the range of 350-500kHz) is used to generate heat capable of causing coagulative necrosis.

About prostate treatment in Basingstoke

In mid-2005, a dedicated Urological Treatment Unit in Basingstoke was initiated. The initial funding for the project was committed in partnership with the Greenham Common Trust in West Berkshire, providing treatment access for both NHS and private patients in the region.

This Unit specialises in delivering current modes of surgical treatment for prostate cancer but, more importantly, pursues advances in technology and techniques to improve treatment for patients across the South of England.

Looking ahead

Consultant Urological Surgeon Richard Hindley has pioneered the use of the high powered KTP (green-light laser) for benign prostate enlargement with considerable success. This vaporises prostate tissue and is set to replace traditional prostate surgery with its inherent side effects of incontinence and impotence.

We are very interested in seeing advances in minimally invasive technology.

High-Intensity Focused Ultrasound (HIFU) employs sound to destroy small prostate cancer tumours, obviating the need for surgical removal, and, as in greenlight laser, reducing the possible side effects from surgery. Pelican is also investigating the use of HIFU for kidney and liver tumours. A HIFU machine has been donated by the Greenham Common Trust to the Basingstoke Unit.

Read more about the ongoing research in London and Basingstoke on focal therapy (HIFU) for prostate cancer in the research section.

Predict Prostate – An individualised prognostic model for men newly diagnosed with non-metastatic prostate cancer.

Predict Prostate is a tool where the outcomes from conservative management (or monitoring) are compared with radical treatment (surgery or radiotherapy).

Simply enter the details about yourself and your prostate cancer, and then select conservative management or radical treatment to see estimates of survival with each.

 

Pelican Cancer FoundationFollow

Driving innovation and advancing surgery to help patients live well, for longer.

Pelican Cancer Foundation
lapcoleadmarkMark Coleman FRCS MD@lapcoleadmark·
12h

Join us on this evidence based course to improve the skills of trainers and aspiring trainers! Now rolling out in centres globally! https://twitter.com/ICENICentre/status/1526559748602085377

Reply on Twitter 1526568932097785858Retweet on Twitter 15265689320977858581Like on Twitter 15265689320977858581Twitter 1526568932097785858
ACPGBI@ACPGBI@ACPGBI·
16 May

Most delighted that @Brendan92855812 past @ACPGBI President will join us to deliver the 2022 Hunterian Lecture at #ACGBI2022 in Edinburgh on Mon 4 Jul at 17:30. Chaired by @ACPGBI President @petesagar7
▶️https://bit.ly/ACPGBI22-4-Jul

Reply on Twitter 1526171048491745280Retweet on Twitter 15261710484917452809Like on Twitter 152617104849174528014Twitter 1526171048491745280
ChrisGBoultonChris Boulton@ChrisGBoulton·
12 May

Today's taster of my Big Mountains Exhibition at the @westridgestudio Highclere on 21/22 May is my triptych of the Monte Rosa Massif. #oswbnh2022 #westridgestudio #artexibition #openstudios #bigmountains #alpsmountains #monterosa #pelicancancerfoundation #mycancermychoices

Reply on Twitter 1524787378711404545Retweet on Twitter 15247873787114045451Like on Twitter 15247873787114045451Twitter 1524787378711404545
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2022 · Outreach Pro Theme on Genesis Framework · WordPress · Log in